Nebenwirkungen · Invanz
INVANZ 1 g powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 5
HOS-109682 · Präparat HOS-093229
Summary of the safety profile Adults The total number of patients treated with ertapenem in clinical studies was over 2 200 of which over 2 150 received a 1 g dose of ertapenem. Adverse reactions (i.e., considered by the investigator to be possibly, probably, or definitely related to the medicinal product) were reported in approximately 20 % of patients treated with ertapenem. Treatment was discontinued due to adverse reactions in 1.3 % of patients. An additional 476 patients received ertapenem as a single 1 g dose prior to surgery in a clinical study for the prophylaxis of surgical site infections following colorectal surgery.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-21T12:39:00Z · SHA-256 13490dcc12f2323c9f05fd475688521f0cede9594f39093b7209e9be58897413 · Passage c723542bfa15dba9de5744b755fbc8f39316224a0a94242648eb5be9d2714c77 · Zeichen 0–635 im Abschnitt